AIF1抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse kidney tissue, Primary antibody: P00439(AIF1 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 4 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P00439(AIF1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P00439(AIF1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The AIF1 (Allograft Inflammatory Factor 1) antibody is a crucial tool for detecting AIF1. a protein encoded by the *AIF1* gene, also known as *IBA1* (Ionized Calcium-Binding Adapter Molecule 1). AIF1 is a 17-kDa calcium-binding protein predominantly expressed in macrophages, microglia, and other immune cells. It plays roles in inflammatory responses, immune regulation, and cellular processes like phagocytosis and apoptosis. AIF1 is implicated in pathological conditions such as neuroinflammation, autoimmune diseases, transplant rejection, and cancer progression.

AIF1 antibodies are widely used in research to identify and study AIF1-expressing cells in tissues, particularly in neurological disorders (e.g., Alzheimer’s disease, multiple sclerosis) and immune-related pathologies. These antibodies enable techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence, helping to visualize microglial activation or macrophage infiltration in disease models.

Commercial AIF1 antibodies are often raised against conserved regions of the protein, ensuring cross-reactivity in humans, mice, and rats. Validation includes testing specificity via knockout controls or siRNA knockdown. Researchers must consider potential cross-reactivity with homologous proteins (e.g., AIF1L) and optimize protocols for specific applications. Understanding AIF1's role through such antibodies advances insights into inflammation-mediated diseases and therapeutic targeting.